Cellyan Biotechnology Co., Ltd

HKPD Healthcare Medical Distribution

Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.

0.11 0.00 0.00%
Market cap
$17.1M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
3.39
Beneish M
−0.76
Dividend safety
n/a
Mar '26 Sep '25 Mar '25 Sep '24 Older periods
ROE
0.00% 0.00% — —

+2 more TTM periods

ROA
0.00% 0.00% — —
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
0.00% 0.00% 0.00% 0.00%
Average Days of Receivables
0.00 0.00 0.00 0.00
Free Cash Flow per Share
0.00 0.00 0.00 —
Free Cash Flow
0.14 0.52 2.41 —
Capital Expenditures
(0.18) (0.17) (0.24) —
Other line items
Cash ROIC
1.34% 5.49% 24.40% 0.00%
Accounts Receivable Turnover
0.00 0.00 — —
Accounts Payable Turnover
0.00 0.00 — —
Inventory Turnover
0.00 0.00 — —
Average Days of Payables
0.00 0.00 0.00 0.00
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Operating CF/Net income
0.00 0.00 0.00 —
Depreciation/Fixed assets
1.02 1.97 0.98 0.00
Capex/Depreciation
(0.75) (0.75) (0.99) —
Operating CF per Share
0.00 0.00 0.00 —
Capex per Share
0.00 0.00 0.00 —
Capex to Sales
0.00 0.00 0.00 —

Fold the line items

Columns are period end dates